commentari
wolf
mc
freiberg
zhang
akyolataman
z
grock
hong
pw
li
j
watson
nf
fang
aq
aguilar
hc
et
al
broadspectrum
antivir
target
entri
envelop
virus
contrast
sever
wide
use
antibiot
antivir
drug
typic
target
singl
viru
rise
number
divers
emerg
endem
viral
diseas
pose
signific
health
risk
human
popul
underscor
need
develop
broadspectrum
antivir
howev
broadspectrum
antivir
licens
limit
potenc
poorli
toler
theoret
broadspectrum
antivir
compound
could
target
conserv
host
pathway
protein
support
infect
multipl
virus
common
viral
structur
featur
exampl
host
proteas
potenti
target
broadspectrum
antivir
sinc
mani
virus
ebola
reoviru
coronaviru
requir
host
proteas
entri
addit
host
enzym
imp
dehydrogenas
target
ribavirin
requir
replic
sever
rna
dna
virus
current
phase
ii
clinic
trial
treatment
influenza
favipiravir
also
inhibit
sever
rna
virus
like
select
inhibit
viral
rnadepend
rna
polymeras
recent
pna
studi
wolf
et
al
describ
discoveri
character
promis
broadspectrum
antivir
compound
show
activ
impress
number
envelop
virus
aryl
methyldien
rhodanin
deriv
found
highthroughput
cellbas
screen
inhibitor
nipah
viru
niv
entri
use
vesicular
stomat
viru
vsv
luciferas
report
pseudotyp
system
caus
minim
cellular
toxic
vitro
inhibitori
concentr
author
employ
sever
independ
approach
show
act
level
viru
entri
exampl
inhibit
achiev
ad
viru
absorpt
onto
cell
ad
viru
adsorpt
infect
occur
normal
betalactamas
content
mix
assay
demonstr
role
entri
though
bind
assay
show
viral
attach
occur
normal
thu
implic
virusmembran
fusion
potenti
target
point
activ
resembl
inhibitor
act
earli
stage
viral
lifecycl
howev
becam
evid
show
antivir
activ
nipah
viru
also
impress
array
virus
includ
repres
filovirida
orthomyxovirida
arenavirida
bunyavirida
paramyxovirida
flavivirida
retrovirida
poxvirida
rhbdovirida
member
adenovirida
picornovirida
reovirida
result
antivir
activ
independ
viral
glycoprotein
respons
mediat
viru
entri
unifi
structur
featur
evid
amongst
divers
virus
inhibit
presenc
viral
membran
inhibit
envelop
virus
test
fail
inhibit
nonenvelop
virus
aid
intrins
fluoresc
author
show
associ
liposom
liposom
compet
nivpseudotyp
vsv
unless
virion
pretreat
addit
liposom
author
suggest
intercal
viral
membran
essenti
irrevers
manner
prevent
membran
fusion
manner
independ
viral
membran
fusion
protein
support
propos
viral
glycoproteinindepend
mechan
action
author
attempt
gener
resist
hiv
mutant
serial
passag
yet
resist
viru
fail
develop
four
week
longer
passag
studi
well
use
addit
strain
virus
test
thu
far
may
provid
clue
mechan
action
address
import
issu
whether
resist
gener
anoth
unansw
question
whether
intercal
preferenti
viral
membran
whether
associ
equal
well
lipid
bilay
regardless
specif
protein
lipid
content
without
degre
membran
specif
difficult
envisag
achiev
high
enough
level
vivo
prove
effect
system
administr
becom
impract
topic
formul
may
feasibl
antiherpesviru
drug
docosanol
abreva
importantli
associ
viral
membran
potent
enough
protect
mice
infect
lethal
dose
ebola
rift
valley
fever
viru
virion
pretreat
prior
inocul
anim
though
associ
viral
host
membran
viral
membran
whose
function
appear
impair
inhibit
viruscel
fusion
fail
inhibit
cellcel
fusion
reaction
mediat
viral
glycoprotein
author
hypothes
due
fact
host
membran
continu
remodel
repair
metabol
extract
membraneact
agent
thu
escap
gross
membran
perturb
consist
synergist
disrupt
plasma
membran
integr
observ
cell
expos
inhibitor
fatti
acid
synthesi
tofa
suggest
simpli
associ
lipid
membran
suffici
antivir
activ
though
precis
mechan
yet
determin
one
mechan
could
potenti
prevent
fusion
alter
membran
curvatur
varieti
nonbilay
lipid
impact
membran
curvatur
shown
inhibit
fusion
membran
target
broadspectrum
antivir
develop
vari
degre
success
cosalan
thought
associ
viral
membran
show
activ
hiv
herp
virus
vitro
howev
due
hydrophob
properti
effort
focus
maxim
bioavail
tissu
clearanc
earli
studi
docosanol
abreva
satur
alcohol
show
activ
sever
envelop
virus
found
bind
viral
membran
current
licens
topic
cream
treatment
herp
cold
sore
arbidol
indol
deriv
current
licens
russia
treat
acut
respiratori
infect
like
arbidol
strong
affin
membran
show
wide
spectrum
activ
sever
envelop
also
nonenvelop
virus
mechan
action
arbidol
entir
clear
recent
studi
hcv
show
similar
discoveri
serv
import
proof
principl
global
unbias
approach
toward
screen
antivir
compound
tradit
vitro
enzymat
screen
approach
led
develop
potent
highli
specif
antivir
agent
cellbas
screen
undertaken
wolf
et
al
may
prove
even
success
drug
discoveri
part
biolog
activ
toxic
upfront
criteria
choos
lead
compound
factor
often
halt
progress
otherwis
promis
compound
sidestep
expens
undertak
biolog
target
valid
must
preced
vitrobas
screen
livecel
screen
approach
also
afford
opportun
identifi
antivir
agent
target
aspect
viru
lifecycl
includ
compound
target
conserv
host
cell
compon
rather
viral
protein
unpreced
activ
numer
envelop
virus
rais
possibl
effect
broadspectrum
antivir
identifi
